BIOMÉRIEUX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.3 EUR | -1.05% |
|
-1.00% | -6.26% |
| 05-10 | BioMérieux: the rebound gains momentum, an analyst reinforces its case | CF |
| 04-26 | BioMérieux: share price rises, analyst remains Buy | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.9B 4.24B 5.77B | Sales 2025 * | 4.19B 4.55B 6.21B | Capitalization | 11.14B 12.1B 16.5B |
|---|---|---|---|---|---|
| Net income 2024 * | 467M 507M 691M | Net income 2025 * | 527M 572M 780M | EV / Sales 2024 * | 2.79 x |
| Net cash position 2024 * | 263M 286M 390M | Net cash position 2025 * | 444M 482M 657M | EV / Sales 2025 * | 2.55 x |
| P/E ratio 2024 * |
24.4
x | P/E ratio 2025 * |
21.6
x | Employees | 13,696 |
| Yield 2024 * |
0.92% | Yield 2025 * |
1.06% | Free-Float | 36.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More recommendations
More press releases
More news
| 1 day | -1.05% | ||
| 1 week | -1.00% | ||
| Current month | -5.70% | ||
| 1 month | -5.27% | ||
| 3 months | -9.67% | ||
| 6 months | -1.95% | ||
| Current year | -6.26% |
1 week
93.80
97.00
1 month
93.80102.90
Current year
93.80108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 14 M€ | -2.76% | ||
| 0.26% | 1,083 M€ | +4.63% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 94.3 | -1.05% | 78,441 |
| 24-05-20 | 95.3 | -0.63% | 81,148 |
| 24-05-17 | 95.9 | -0.10% | 130,605 |
| 24-05-16 | 96 | +0.05% | 150,893 |
| 24-05-15 | 95.95 | +0.73% | 235,050 |
Real-time Euronext Paris, May 21, 2024 at 11:35 am
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
94.3
EUR
Average target price
113.4
EUR
Spread / Average Target
+20.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.26% | 12.23B | |
| -3.93% | 8.17B | |
| +7.10% | 5.78B | |
| +30.16% | 5.74B | |
| -7.47% | 4.24B | |
| -57.20% | 2.97B | |
| +12.56% | 2.73B | |
| -4.67% | 2.38B | |
| +27.38% | 2.26B | |
| -4.21% | 1.87B |
- Stock Market
- Equities
- BIM Stock
